Skip to main content
 This program is not active.
On Demand

Making the Diagnosis of Diabetes, Shared Medical Appointments in Primary Care & Classes of Hypoglycemic Diabetic Medications


Total Credits: 2 including 2.0 AOA Category 1-A Credit(s)

Average Rating:
   3
State Associations:
WOMA - Washington
Faculty:
H. Ken Cathcart, D.O. |  Greg Heinicke, DO |  Katina Rue, D.O. |  Kim Wadsworth, DO |  William Elliott, M.D. Ph.D.
Duration:
1 Hour 50 Minutes
Expiration:
Never expires.


Description

Making the Diagnosis of Diabetes Mellitus

The attendee will be able to use the FBS, the standard 2 hr glucose tolerance test, or the hemoglobin A1C test to make the diagnosis of diabetes; understand how to make the diagnosis of type 1 diabetes mellitus, type 2 diabetes mellitus, and LADA understand why it is important to know the difference between a type 1 diabetic, a type 2 diabetic, and a LADA patient.

 

Shared Medical Appointments in Primary Care​

Shared medical appointments (SMAs), or group visits, offer an innovative, interactive approach to healthcare that brings a group of patients with common needs together with one or more healthcare providers in a shared appointment that is typically 90 minutes long, allowing participants to spend more time with the healthcare team. There is a growing discussion among providers looking for ways to enhance access and productivity in primary care, and SMAs have demonstrated improvement in access, cost, disease management outcomes, patient-centered care and provider satisfaction—achieving the Quadruple Aim. In this session, we hope to inspire you to design, implement and evaluate SMAs in your practice.

 

Classes of Hypoglycemic Diabetic Medications

This 50-minute session will briefly summarize the world’s epidemiological literature comparing the incidence of various cardiovascular endpoints in individuals with and without diabetes mellitus at baseline. Since it was originally thought that the primary mediator of increased cardiovascular risk among diabetics was simply their dysglycemia, several clinical trials were organized to test the hypothesis that more intensive glucose lowering would lead to a reduced risk of cardiovascular events; sadly, the results of these studies were inhomogeneous. In the last several years, long-term results of several of these studies have been published, which adds only a little clarity to the proposition that tight control of plasma glucose is beneficial. The most recent studies that suggest a cardiovascular benefit of more intensive glucose lowering are: EMPA-REG, LEADER, and SUSTAIN-6. At the risk of being disingenuous, because several of these included in their factorial design, an arm comparing blood pressure targets in the same patients (in whom glycemic control was separately randomized), it is possible to compare the effects of glycemic and blood pressure control, the latter of which appears to be more beneficial (as long as it is sustained). As a result, nearly all authorities now recommend a multi-pronged approach to reducing cardiovascular risk in people with diabetes. The best evidence for the efficacy of such an approach comes from the STENO-2 trial, done in Denmark, which showed not only improved cardiovascular outcomes in its original 7.8-year follow-up, but also reduced all-cause mortality when median follow-up was extended to 13.3 years.

 

The Washington Osteopathic Medical Association is accredited by the American Osteopathic Association as a Category 1 CME Sponsor.

 

The WOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions, or complaints should be forwarded to WOMA Executive Director Roseanne Andersen, by calling the WOMA Office at 425-677-3930 or by mail to WOMA, P.O. Box 1187 Gig Harbor, WA 98332 or by email to executivedirector@woma.org

Faculty

H. Ken Cathcart, D.O.'s Profile

H. Ken Cathcart, D.O. Related Seminars and Products


Ken Cathcart is a graduate of the Philadelphia College of Osteopathic Medicine.  His postgraduate training includes an internship and internal medicine residency at Doctors Hospital in Columbus, Ohio where he served as Chief Resident in 1987-88.  He completed a Fellowship in Endocrinology and Metabolism at Baystate Medical Center, Tufts University, in 1990.  HE is AOBIM certified in Endocrinology and Metabolism and a Fellow of the American College of Endocrinology.  He practices General Endocrinology and Metabolism at Northside Internal Medicine in Spokane.

 

CV

Faculty Disclosure





William Elliott, M.D. Ph.D.'s Profile

William Elliott, M.D. Ph.D. Related Seminars and Products

Chair, Department of Biomedical Sciences

Pacific NW University of Health Sciences College of Osteopathic Medicine


William J. Elliott, M.D., Ph.D. is Professor of Preventive Medicine,  Internal Medicine, and Pharmacology, Chief of the Division of Pharmacology, and Chair of The Department of Biomedical Sciences at the Pacific Northwest University of Health Sciences in Yakima, WA. After receiving the B.S. (summa cum laude) from the University of Notre Dame, he earned the M.D. and Ph.D. (in Bio-Organic Chemistry) from the University of Chicago. He trained in Internal Medicine and Pharmacology at Barnes Hospital and Washington University—St. Louis, and served as a member of the faculty of the University of Chicago from 1985-92. During the next 17 years at RUSH Medical College, he practiced, taught and did research on cardiovascular clinical pharmacology, focusing on epidemiologic studies of risk factors (including diagonal earlobe creases), laboratory investigations, federally-funded cooperative clinical trials, and many industry-supported endeavors, serving as principal investigator for about 200 clinical trials of new drugs.  Dr. Elliott holds Board Certification in both Internal Medicine and Clinical Pharmacology. One of the inaugural “Specialists in Clinical Hypertension” and Fellows of the American Society of Hypertension, he contributed on five topics to  JNC VI, as well as to the “long version” of JNC 7. Some of his recent publications include meta-analyses of clinical trial results, putative risk factors for cardiovascular disease, cost-containment, pharmacoeconomics, and the assessment and enhancement of medication adherence. Dr. Elliott belongs to many professional societies interested in clinical pharmacology and in hypertension, including fellowship in the American Heart Association’s High Blood Pressure Council. He has lectured on five continents, participated in the review process for many journals, societies, study sections, and funding agencies, and served as editor or co-editor for many books, monographs, and symposia. Among his honors are 29 awards for teaching excellence.

Dr. William Elliott discloses that he has author and editor relationships with Elsevier and Wolters Kluwer for which he received royalties. He discloses that he has no other relevant financial relationships with any organization producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients relative to the content of his presentation. 


Reviews

5
4
3
2
1

Overall:      4

Total Reviews: 3